Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Relypsa Begins Phase 2b Clinical Trial For RLY5016
Relypsa has initiated patient enrollment in the PEARL-HF study, a phase 2b clinical trial of the company’s lead compound, RLY5016. Its a novel potassium binder designed for chronic
Relypsa has initiated patient enrollment in the PEARL-HF study, a phase 2b clinical trial of the company’s lead compound, RLY5016. Its a novel potassium binder designed for chronic
Amarillo Biosciences (ABI) has agreed to a strategic partnership with Intas Pharmaceuticals (Intas), whereby Intas will sponsor clinical trials of ABI’s orally administered interferon-alpha lozenges in order to
Zelos Therapeutics (Zelos) has initiated patient dosing in a single dose study of three proprietary subcutaneous formulations of ZT-034 (hPTH (1-34), teriparatide). ZT-034 is being developed to compete
Idera Pharmaceuticals (Idera) has initiated phase I clinical trial for IMO-2125 in combination with ribavirin for the treatment of naive patients with chronic hepatitis C virus (HCV) infection.
Avanir Pharmaceuticals has received a ‘Notice of Allowance’ from the US Patent and Trademark Office (USPTO) for Zenvia. USPTO intends to grant the company a new patent, extending
Cipher Pharmaceuticals (Cipher) has enrolled first patient in its phase III safety study of Cip-Isotretinoin, the company’s patented formulation of isotretinoin, used in the treatment of severe, nodular
Aeolus Pharmaceuticals (Aeolus) has reported that AEOL 10150 protects lungs from whole mustard gas exposure in rats, based on the series of preliminary studies conducted by National Jewish
Kylin Therapeutics have received a notice of allowance from the US Patent and Trademark Office for its first US patent application. The newly allowed patent, exclusively licensed to
The FDA has approved Daiichi Sankyo’s (DSI) supplemental new drug application for Welchol (colesevelam HCl), to be used as an adjunct to diet and exercise for the reduction
Vical Incorporated’s TransVax cytomegalovirus (CMV) vaccine continued to demonstrate an overall increase in cellular immune responses compared with placebo, at the seven-month immunogenicity data point in an ongoing